Clinical correlations with EGFR circulating tumor DNA testing in all-stage lung adenocarcinoma
BACKGROUND: Information on genetic alterations, notably EGFR mutations, is important for guiding non-small-cell lung cancer (NSCLC) treatment. Circulating tumor DNA (ctDNA) analysis represents a less invasive alternative to tissue biopsy for analyzing mutation status, but its clinical value may vary...
Saved in:
Main Author: | Incharoen P. |
---|---|
Other Authors: | Mahidol University |
Format: | Article |
Published: |
2023
|
Subjects: | |
Online Access: | https://repository.li.mahidol.ac.th/handle/123456789/82330 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Institution: | Mahidol University |
Similar Items
-
Cell-penetrable nanobodies (transbodies) that inhibit the tyrosine kinase activity of EGFR leading to the impediment of human lung adenocarcinoma cell motility and survival
by: Lueacha Tabtimmai, et al.
Published: (2020) -
Detection and dynamic changes of EGFR mutations from circulating tumor DNA as a predictor of survival outcomes in NSCLC Patients treated with first-line intercalated erlotinib and chemotherapy
by: Tony Mok, et al.
Published: (2018) -
Prognostic evaluation of tumor-stroma ratio in patients with early stage cervical adenocarcinoma treated by surgery
by: Tip Pongsuvareeyakul, et al.
Published: (2018) -
Clinical outcome of treatment of metastatic non-small cell lung cancer in patients harboring uncommon EGFR mutation
by: J. Chantharasamee, et al.
Published: (2020) -
T790M mutations identified by circulating tumor DNA test in lung adenocarcinoma patients who progressed on first-line epidermal growth factor receptor-tyrosine kinase inhibitors
by: Virodini Merinda, -, et al.
Published: (2019)